Pulmocide Ltd, a London, UK-based drug discovery company developing novel compounds designed for inhaled delivery to treat respiratory syncytial virus (RSV) and pulmonary aspergillosis, completed a $30.4m Series B financing round.
The round was led by new investor SR One and included Longwood Fund plus existing investors SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. and Touchstone Innovations plc.
Led by Dr Garth Rapeport, Chief Executive Officer, Pulmocide develops novel small molecule inhaled medicines for the treatment of life threatening respiratory infections caused by RSV and Aspergillus.
The company intends to use the proceeds to progress its wholly-owned assets through early clinical development. Pulmocide is on track to deliver proof of concept data in RSV with its highly potent inhaled RSV antiviral agent (PC786) in human RSV challenge and in infants hospitalised with bronchiolitis due to RSV infection and will also be progressing PC945, a potent azole antifungal for the treatment of pulmonary Aspergillosis, including fungal asthma, pulmonary Aspergilloma, Aspergillus infections in lung transplant recipients and patients with cystic fibrosis.